fect their growth rate when telomeric repeats finally run out (9) . However, efficient inhibition of telomerase expression has been seen to potentially induce apoptosis in a few days (10, 11) , and this is irrespective of its traditional telomer-lengthening function. It has been currently suggested that, in addition to this function, telomerase may be necessary to protect chromosome ends against their being acknowledged as DNA disruptions, which would trigger mechanisms for apoptosis or cell cycle termination (12) . This notion is consistent with recent findings demonstrating transient low-level telomerase expression during the S phase in non-modified human somatic cells (13) . In view of these reports, the need to assess the effect complete, permanent inhibition of telomerase may exert on normal cells stands out. Regarding Ras inhibition, the potential to induce cell death may partly depend on a restoration of the p53 route, which was previously repressed by Ras (14) . Through Ras actions tumor cells under several genetic and metabolic insults may survive and divide despite such strong proapoptotic stimuli. However, just because of tumor cells' severe unstability, their ability to select mutants adapted to the inhibition of specific routes is very high. In this respect the approach described by Lledó et al. (5), based on the simultaneous inhibition of several tumorigenic mechanisms using ASOs, is most interesting. This strategy is reminiscent of the association of several chemotherapeutic agents in order to overcome the resistance of tumor cells to apoptosis.
Secondly, the possibility to reach in vivo an adequate level of inhibiting molecules to reproduce effects seen under cell culture conditions should be assessed, considering that many other factors may reduce treatment efficacy in humans. As an example, ISIS 2503, an ASO designed to counter H-ras oncogene, has been clinically used at doses above 6 mg/kg/day intravenously, which resulted in plasma levels of 4 µg/ml (15). This would have been theoretically equivalent to an intratumoral concentration greater than 0.1 µmol/l, which is the average IC 50 reported in vitro for most tumor cells. However, no clear antitumoral effect could be demonstrated. Vectors may be an alternative in order to improve ASO bioavailability. From a pharmacological viewstand this increases system complexity and may result in new difficulties. However, the power, stability, and antitumoral specificity of vectors chosen will determine not only the biological effects on tumor cells, but also the presence or absence of adverse effects on surrounding tissues.
